Viatris Inc (VTRS)

05:18 AM

Viatris Inc. stock rises Monday, outperforms market - MarketWatch

05:18 AM

12:50 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc.VTRS - PR Newswire

12:50 PM

10:18 AM

Viatris ‘Actively Launching’ Glucagon As It Looks To Deliver On Pipeline Promise - Citeline News & Insights

10:18 AM

09:52 AM

Viatris Inc. rating downgraded by S&P due to high leverage expectations - Investing.com Australia

09:52 AM

Mar 02, 2025

Viatris outlines $450M-$550M product revenue target for 2025 while addressing Indore impact - MSN

Mar 02, 2025

Mar 02, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Viatris Inc. (VTRS) Investors to Inquire about Securities Investigation - Markets Insider

Mar 02, 2025

Mar 02, 2025

Tesla, Palantir And MicroStrategy Are Among Top 12 Large-Cap Losers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio? - Benzinga

Mar 02, 2025

Mar 01, 2025

Is Viatris Inc. (VTRS) the Best Weight Loss Drug Stock to Buy According to Analysts? - Insider Monkey

Mar 01, 2025

Mar 01, 2025

Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris - GlobeNewswire

Mar 01, 2025

Feb 28, 2025

Here's What Key Metrics Tell Us About Viatris (VTRS) Q4 Earnings - Nasdaq

Feb 28, 2025

Feb 28, 2025

Viatris Inc. stock falls Friday, underperforms market - MarketWatch

Feb 28, 2025

Feb 28, 2025

Stock Of The Day: Why The Viatris Meltdown Ended Where It Did - Benzinga

Feb 28, 2025

Feb 28, 2025

Lost Money on Viatris Inc. (VTRS)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire

Feb 28, 2025

Feb 28, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Viatris Inc. (VTRS) And Encourages Investors to Reach Out - Markets Insider

Feb 28, 2025

Feb 28, 2025

Barclays Adjusts Price Target on Viatris to $9 From $12, Keeps Underweight Rating - Marketscreener.com

Feb 28, 2025

Feb 28, 2025

Why Viatris Inc. (VTRS) Went Down on Thursday - MSN

Feb 28, 2025

Feb 28, 2025

Viatris Rocked By Indore US Block, With $500m Revenue Sting Anticipated In 2025 - Citeline News & Insights

Feb 28, 2025

Feb 28, 2025

Viatris Inc. (NASDAQ:VTRS) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025

Feb 28, 2025

Viatris Inc.: A Comprehensive Analysis of Financial Performance, Strategic Initiatives, and Market Challenges - HPBL

Feb 28, 2025

Feb 28, 2025

Viatris plummets sharply on disappointing fourth-quarter, 2025 outlook - Investing.com

Feb 28, 2025

Feb 28, 2025

Nxera Pharma clinches millions from autoimmune disease deal - Business Weekly

Feb 28, 2025

Feb 28, 2025

Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale - ACCESS Newswire

Feb 28, 2025

Feb 28, 2025

Viatris: Q4 Earnings Snapshot - Thehour.com

Feb 28, 2025

Feb 27, 2025

Viatris Reports Strong 2024 Financial Results - TipRanks

Feb 27, 2025

Feb 27, 2025

Viatris, Inc. Earnings Call: Balancing Growth and Challenges - TipRanks

Feb 27, 2025

Feb 27, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Viatris Inc. (VTRS) And Encourages Stockholders to Reach Out - Markets Insider

Feb 27, 2025

Feb 27, 2025

Nxera Pharma Assigns Cenerimod Rights to Viatris for Japan and APAC - TipRanks

Feb 27, 2025

Feb 27, 2025

Viatris Inc. stock falls Thursday, underperforms market - MSN

Feb 27, 2025

Feb 27, 2025

Viatris' 2025 Looks Shaky From Site Inspection but Future Launches and Pipeline Support Our Outlook - Morningstar

Feb 27, 2025

Feb 27, 2025

Viatris Inc SEC 10-K Report - TradingView

Feb 27, 2025

Feb 27, 2025

Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges - MSN

Feb 27, 2025

Feb 27, 2025

Viatris Inc to Host Earnings Call - ACCESS Newswire

Feb 27, 2025

Feb 27, 2025

Viatris Stock Tumbles On Q4 Earnings Miss, FDA Warning Clouds 2025 Outlook - Benzinga

Feb 27, 2025

Feb 27, 2025

Viatris Shares Drop After Q4 Results Miss Consensus -February 27, 2025 at 12:49 pm EST - Marketscreener.com

Feb 27, 2025

Feb 27, 2025

Viatris launches global review, plans aggressive share buybacks - The Business Journals

Feb 27, 2025

Feb 27, 2025

Viatris is Oversold - Nasdaq

Feb 27, 2025

Feb 27, 2025

Drugmaker Viatris forecasts weak 2025 results after import curbs on India plant -February 27, 2025 at 11:15 am EST - Marketscreener.com

Feb 27, 2025

Feb 27, 2025

Drugmaker Viatris forecasts weak 2025 results after import curbs on India plant - Reuters

Feb 27, 2025

Feb 27, 2025

Viatris: One Swallow Doesn't Make A Summer (NASDAQ:VTRS) - Seeking Alpha

Feb 27, 2025

Feb 27, 2025

Viatris plummets sharply on disappointing fourth-quarter, 2025 outlook By Investing.com - Investing.com Australia

Feb 27, 2025

Feb 27, 2025

Earnings call transcript: Viatris Inc Q4 2024 misses EPS estimates, stock dives - Investing.com

Feb 27, 2025

Feb 27, 2025

Is Viatris Inc. (VTRS) the Best Low Price Pharma Stock to Invest In Right Now? - Insider Monkey

Feb 27, 2025

Feb 27, 2025

Viatris slides as FDA scrutiny on India plant clouds outlook - MSN

Feb 27, 2025

Feb 27, 2025

Drugmaker Viatris forecasts weak 2025 results after import curbs on India plant -February 27, 2025 at 08:18 am EST - Marketscreener.com

Feb 27, 2025

Feb 27, 2025

Viatris stock slides after Q4 2024 miss (VTRS:NASDAQ) - Seeking Alpha

Feb 27, 2025

Feb 27, 2025

Viatris (VTRS) Q4 Earnings and Revenues Lag Estimates - Yahoo Finance

Feb 27, 2025

Feb 27, 2025

Viatris Inc. Announces Quarterly Dividend, Payable on March 18, 2025 -February 27, 2025 at 06:30 am EST - Marketscreener.com

Feb 27, 2025

Feb 27, 2025

Viatris' Q4 Adjusted Earnings, Revenue Fall; Provides 2025 Guidance -February 27, 2025 at 07:20 am EST - Marketscreener.com

Feb 27, 2025

Feb 27, 2025

Viatris shares tumble over 5% as Q4 results miss estimates, 2025 outlook disappoints - Investing.com

Feb 27, 2025